Featured

December 5, 2023

Alto Neuroscience’s Precision Psychiatry Platform Fuels Third Positive Phase II Readout

December 4, 2023

Alto Neuroscience's CEO on why MDD data may validate its precision medicine approach

January 10, 2023

Alto touts new PhIIa depression data with plans to keep charging forward

December 5, 2023
Alto Neuroscience’s Precision Psychiatry Platform Fuels Third Positive Phase II Readout
December 4, 2023
Alto Neuroscience's CEO on why MDD data may validate its precision medicine approach
January 10, 2023
Alto touts new PhIIa depression data with plans to keep charging forward

In the News

All News

Alto’s Neuropsychiatric Platform Scores Third Mid-Stage Win

December 5, 2023

Alto Neuroscience’s Precision Psychiatry Platform Fuels Third Positive Phase II Readout

December 5, 2023

Alto's precision psychiatry approach further validated as 2nd med improves depression symptoms

December 4, 2023

Alto Neuroscience unveils efficacy signal from PhIIa MDD trial with machine learning-identified biomarker

December 4, 2023

Early signs Alto’s precision neuropsychiatry approach may be working

December 4, 2023

Alto Neuroscience's CEO on why MDD data may validate its precision medicine approach

December 4, 2023
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
our story
team
join us
platform
publications
programs
press releases
in the news
AI tools
alto in mind
Alto In Mind
contact
Alto Neuroscience
369 South San Antonio Road
Los Altos, CA 94022
info@altoneuroscience.com
Receive updates from Alto
Thanks for signing up!
Oops! Something went wrong while submitting the form.
Privacy Policy
Terms of Use
© Alto Neuroscience 2023
‍